RxION Health review

RxION publishes a price for every molecule on its anti-aging shelf — sermorelin $299, NAD⁺ $249, glutathione $224 — and holds each one flat at every dose, which removes the most common way a cheap-looking peptide plan gets expensive. It goes further than most sellers on one page: its NAD⁺ listing states plainly that compounded NAD⁺ is not FDA-approved for anti-aging, energy, cognitive or longevity indications, printed directly under the buy button. It also names a medical director and a mailing address. What it will not tell you is which pharmacy prepares the medication, and the refund policy keeps a $75 consultation fee if you are turned down.

RxION Health is a telehealth platform organized in three bands: weight management (compounded semaglutide and tirzepatide, branded Wegovy and Zepbound, LIPO-B and a microdose GLP-1 program), anti-aging and longevity (sermorelin, NAD⁺ and glutathione, all compounded injectables), and sexual health (PT-141). The operating company is RxION Health, Inc., with a mailing address in Greenwood Village, Colorado, and its medical director is Alok Kushwaha, MD, described as board-certified in internal medicine and obesity medicine. Every anti-aging product is sold as a monthly supply with the consultation, medication if prescribed, free cold-pack overnight shipping, all injection supplies and instructions, and ongoing clinical support inside a single figure.

A four-step storefront flow: pick the medication, complete a secure online intake, a licensed provider reviews it and decides whether treatment is appropriate, and if approved the prescription ships from a licensed US pharmacy in temperature-conscious packaging. The site is explicit that no medication is dispensed without provider approval and that not all patients will be eligible, and that the price reflects the consultation plus medication if prescribed — which is honest framing for a pay-first model. Its quality-control disclosure is unusually concrete: batches tested for potency to within ±10% of the labeled concentration every three to six months, pH balance to limit injection-site irritation, sterility to USP <797> standards, and endotoxins held under the USP <85> thresholds. Stating the actual standards rather than saying "lab-tested" is a meaningful difference. The identity layer is solid: a named medical director, a phone number, a Colorado mailing address and the corporate name in its terms, which set Florida law with disputes heard in Miami-Dade County. What is missing is the pharmacy — partner pharmacies are described as licensed and FDA-regulated but never named. Read the refund policy before paying: if you are not approved, you get back the medication portion only, and the $75 consultation fee is non-refundable; a refill canceled after renewal but before provider review costs a 7.5% fee; and nothing is refundable once a prescription has gone to the pharmacy. It does not take insurance, HSA or FSA payments. Coverage is stated by exclusion — not available to residents of New Jersey, Alaska or Mississippi — rather than as a positive state list. The site also displays an aggregate patient score, which is not independent evidence and plays no part in this assessment.

Published, flat and per-molecule, which is the reason to look. Sermorelin is $299 a month, NAD⁺ $249 a month and glutathione $224 a month, each stated as the same price at every dose with no surprise increases, and each including the provider consultation, the medication if prescribed, free cold-pack overnight shipping, all supplies and step-by-step injection instructions, and ongoing clinical support. The flat-at-every-dose promise is the substantive part: on a therapy your provider is expected to titrate, a plan priced by dose can double between month one and month six, and this one cannot. Sermorelin at $299 is a high price for sermorelin, and glutathione at $224 sits above several peers, so this is transparency rather than value — you are paying a premium for a price that does not move. What is not stated anywhere is dose, concentration or vial size, so a month is undefined in volume terms; ask before subscribing, since that is what separates $299 here from a lower figure elsewhere. PT-141 is priced the same way at $224 a month. Note that the flat figure is not fully refundable if a provider declines you: $75 of it is a consultation fee the refund policy keeps. Its GLP-1 line is priced separately at $199 a month for semaglutide and $299 for tirzepatide with promotional rates running below both — those are weight-loss numbers and are not a peptide price.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. RxION's NAD⁺ page carries the disclosure this whole category should carry and mostly does not: compounded NAD⁺ is not FDA-approved for anti-aging, energy, cognitive or longevity indications, individual responses vary, and use is at the discretion of a licensed provider after evaluation — printed on the page selling the product rather than in a footer. That is worth more than most trust badges. Compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are, and RxION does not name the pharmacy preparing them. On the evidence, the shelf is not one thing. Sermorelin is a GHRH analog that prompts your own pituitary to release growth hormone, preserving the somatostatin feedback loop injected HGH overrides — a real, well-characterized mechanism whose long-term human outcome data thins out badly past short-term IGF-1 changes. Injected NAD⁺ has no controlled human outcome trials at all; the single human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears from plasma quickly, and the forms with human trial data are the oral precursors NR and NMN, which raise blood NAD⁺ — a biomarker, not an outcome. Injectable glutathione has essentially no controlled human outcome data behind the detoxification, immune and skin claims made for it. PT-141 is the exception in the other direction: the injectable bremelanotide is FDA-approved, but only for generalized hypoactive sexual desire disorder in premenopausal women, so any other use is off-label and a compounded version is not the approved product. Individual results vary.